Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Pipeline Review, H1 2018
Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Pipeline Review, H1 2018
SUMMARY
Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) pipeline Target constitutes close to 37 molecules. Out of which approximately 29 molecules are developed by companies and remaining by the universities/institutes.
The latest report Transient Receptor Potential Cation Channel Subfamily V Member 1 - Pipeline Review, H1 2018, outlays comprehensive information on the Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - The transient receptor potential cation channel subfamily V member 1 (TrpV1) is a protein encoded by the TRPV1 gene. It belongs to a sub-family of the transient receptor potential protein group. It mediates proton influx and may be involved in intracellular acidosis in nociceptive neurons. It is involved in mediation of inflammatory pain and hyperalgesia. It sensitized by a phosphatidylinositol second messenger system activated by receptor tyrosine kinases, which involves PKC isozymes and PCL. It is activated by endogenous compounds, including 12-hydroperoxytetraenoic acid and bradykinin.
It acts as ionotropic endocannabinoid receptor with central neuromodulatory effects. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 9, 6, 10 and 1 respectively. Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 6 and 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Musculoskeletal Disorders, Cardiovascular, Metabolic Disorders, Dermatology, Gastrointestinal, Genito Urinary System And Sex Hormones, Ophthalmology, Immunology, Oncology and Respiratory which include indications Osteoarthritis Pain, Cancer Pain, Inflammatory Pain, Muscle Spasm, Muscle Spasticity, Neuro Muscular Disorders, Neuropathic Pain, Pain, Postherpetic Neuralgia, Acute Pain, Chronic Pain, Congestive Heart Failure (Heart Failure), Diabetic Peripheral Neuropathy, Pruritus, Abdominal Pain, Alzheimer's Disease, Atherosclerosis, Atopic Dermatitis, Autoimmune Hepatitis, Breast Cancer, Cardiomegaly, Cluster Headache Syndrome, Cough, Crohn's Disease (Regional Enteritis), Demyelinating Diseases, Inflammation, Insomnia, Keratoconjunctivitis sicca (Dry Eye), Morton Metatarsalgia, Ocular Hypertension, Ocular Pain, Open-Angle Glaucoma, Overactive Bladder, Post-Operative Pain, Prostate Cancer, Radiculopathy, Renal Failure, Rosacea, Seborrhea, Squamous Cell Carcinoma, Type 2 Diabetes and Visceral Pain.
Furthermore, this report also reviews key players involved in Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) pipeline Target constitutes close to 37 molecules. Out of which approximately 29 molecules are developed by companies and remaining by the universities/institutes.
The latest report Transient Receptor Potential Cation Channel Subfamily V Member 1 - Pipeline Review, H1 2018, outlays comprehensive information on the Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - The transient receptor potential cation channel subfamily V member 1 (TrpV1) is a protein encoded by the TRPV1 gene. It belongs to a sub-family of the transient receptor potential protein group. It mediates proton influx and may be involved in intracellular acidosis in nociceptive neurons. It is involved in mediation of inflammatory pain and hyperalgesia. It sensitized by a phosphatidylinositol second messenger system activated by receptor tyrosine kinases, which involves PKC isozymes and PCL. It is activated by endogenous compounds, including 12-hydroperoxytetraenoic acid and bradykinin.
It acts as ionotropic endocannabinoid receptor with central neuromodulatory effects. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 9, 6, 10 and 1 respectively. Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 6 and 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Musculoskeletal Disorders, Cardiovascular, Metabolic Disorders, Dermatology, Gastrointestinal, Genito Urinary System And Sex Hormones, Ophthalmology, Immunology, Oncology and Respiratory which include indications Osteoarthritis Pain, Cancer Pain, Inflammatory Pain, Muscle Spasm, Muscle Spasticity, Neuro Muscular Disorders, Neuropathic Pain, Pain, Postherpetic Neuralgia, Acute Pain, Chronic Pain, Congestive Heart Failure (Heart Failure), Diabetic Peripheral Neuropathy, Pruritus, Abdominal Pain, Alzheimer's Disease, Atherosclerosis, Atopic Dermatitis, Autoimmune Hepatitis, Breast Cancer, Cardiomegaly, Cluster Headache Syndrome, Cough, Crohn's Disease (Regional Enteritis), Demyelinating Diseases, Inflammation, Insomnia, Keratoconjunctivitis sicca (Dry Eye), Morton Metatarsalgia, Ocular Hypertension, Ocular Pain, Open-Angle Glaucoma, Overactive Bladder, Post-Operative Pain, Prostate Cancer, Radiculopathy, Renal Failure, Rosacea, Seborrhea, Squamous Cell Carcinoma, Type 2 Diabetes and Visceral Pain.
Furthermore, this report also reviews key players involved in Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1)
- The report reviews Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Overview
Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Companies Involved in Therapeutics Development
Amgen Inc
Amorepacific Corp
BCN Peptides SA
Centrexion Therapeutics Corp
Daewoong Pharmaceutical Co Ltd
DoNatur GmbH
Flex Pharma Inc
Grunenthal GmbH
Kyowa Hakko Kirin Co Ltd
Medifron DBT Co Ltd
Neurim Pharmaceuticals Ltd
Pila Pharma AB
Sylentis SAU
Toray Industries Inc
Vitality Biopharma Inc
Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Drug Profiles
AMG-986 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CA-008 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CA-011 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CA-016 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cannabidiol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
capsaicin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
capsaicin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CMX-020 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DD-04107 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DWP-05195 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FLX-787 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FLX-788 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FLX-797 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FLX-798 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
K-685 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MCS-18 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MDR-16523 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MDR-652 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit TRPV1 for Inflammatory Pain and Cancer Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MTX-071 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NEO-6860 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NeuP-12 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PAC-14028 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptides to Target TRPV1 for Pain and Itch - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
piromelatine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
QX-314 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
resiniferatoxin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Block TRPV1 for Congestive Heart Failure and Cardiomegaly - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Block TRPV1 for Overactive Bladder - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Block TRPV1 for Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Block TRPV1 for Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate TRPV1 Channel for Pain and Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate TRPV1 for Demyelinating Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Block TRPA1 and TRPV1 for Central Nervous System - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Block TRPV1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tivanisiran - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XEND-0501 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
zucapsaicin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Dormant Products
Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Discontinued Products
Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Product Development Milestones
Featured News & Press Releases
Jan 30, 2018: Revive Therapeutics Advances Research Program of Cannabinoid-Based Therapies Targeting Liver Diseases
Jan 16, 2018: Centrexion Therapeutics Announces Fast Track Designation Granted by FDA to CNTX-4975 for Treatment of Knee Osteoarthritis Pain
Jan 02, 2018: Centrexion Therapeutics Launching Phase 3 Program for CNTX-4975 in Knee Osteoarthritis Pain in 2018
Dec 07, 2017: Concentric Analgesics Receives FDA Fast Track Designation for CA-008 for Post-Surgical Pain
Nov 28, 2017: Enrollment Completed in Flex Pharmas Phase II Exploratory Spasticity Study in MS
Nov 06, 2017: Flex Pharma Reports Positive Topline Data from Exploratory Phase 2 Trial of FLX-787 in ALS
Nov 02, 2017: Concentric Analgesics Launches CA-008 Clinical Development Program in Post-Surgical Pain
Oct 30, 2017: Centrexion Therapeutics Announces Multiple Data Presentations on CNTX-4975 at the American College of Rheumatology Annual Meeting 2017
Oct 30, 2017: NEO6860 Phase II Data to be Presented at the American College of Rheumatology’s Annual Meeting
Oct 19, 2017: The World Health Organization Selects Tivanisiran as the International Nonproprietary Name for SYL1001
Oct 16, 2017: Flex Pharma Initiates CMT Phase 2 Trial with FLX-787 in US
Sep 27, 2017: Revive Therapeutics Applies to FDA for Orphan Drug Designation for Treatment of Autoimmune Hepatitis
Sep 26, 2017: Centrexion Therapeutics to Present Phase 2b data of Osteoarthritis Drug Candidate CNTX-4975 at the 11th Annual Pain and Migraine Therapeutics Summit
Aug 29, 2017: Centrexion Therapeutics to Present 6-Month Efficacy Data on CNTX-4975 for the Treatment of Chronic Pain Associated with Knee Osteoarthritis at PAINWeek 2017
Aug 01, 2017: Flex Pharma Initiates ALS Phase 2 Trial with FLX-787 in US
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Overview
Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Companies Involved in Therapeutics Development
Amgen Inc
Amorepacific Corp
BCN Peptides SA
Centrexion Therapeutics Corp
Daewoong Pharmaceutical Co Ltd
DoNatur GmbH
Flex Pharma Inc
Grunenthal GmbH
Kyowa Hakko Kirin Co Ltd
Medifron DBT Co Ltd
Neurim Pharmaceuticals Ltd
Pila Pharma AB
Sylentis SAU
Toray Industries Inc
Vitality Biopharma Inc
Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Drug Profiles
AMG-986 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CA-008 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CA-011 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CA-016 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cannabidiol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
capsaicin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
capsaicin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CMX-020 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DD-04107 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DWP-05195 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FLX-787 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FLX-788 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FLX-797 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FLX-798 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
K-685 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MCS-18 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MDR-16523 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MDR-652 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit TRPV1 for Inflammatory Pain and Cancer Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MTX-071 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NEO-6860 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NeuP-12 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PAC-14028 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptides to Target TRPV1 for Pain and Itch - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
piromelatine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
QX-314 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
resiniferatoxin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Block TRPV1 for Congestive Heart Failure and Cardiomegaly - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Block TRPV1 for Overactive Bladder - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Block TRPV1 for Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Block TRPV1 for Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate TRPV1 Channel for Pain and Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate TRPV1 for Demyelinating Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Block TRPA1 and TRPV1 for Central Nervous System - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Block TRPV1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tivanisiran - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XEND-0501 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
zucapsaicin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Dormant Products
Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Discontinued Products
Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Product Development Milestones
Featured News & Press Releases
Jan 30, 2018: Revive Therapeutics Advances Research Program of Cannabinoid-Based Therapies Targeting Liver Diseases
Jan 16, 2018: Centrexion Therapeutics Announces Fast Track Designation Granted by FDA to CNTX-4975 for Treatment of Knee Osteoarthritis Pain
Jan 02, 2018: Centrexion Therapeutics Launching Phase 3 Program for CNTX-4975 in Knee Osteoarthritis Pain in 2018
Dec 07, 2017: Concentric Analgesics Receives FDA Fast Track Designation for CA-008 for Post-Surgical Pain
Nov 28, 2017: Enrollment Completed in Flex Pharmas Phase II Exploratory Spasticity Study in MS
Nov 06, 2017: Flex Pharma Reports Positive Topline Data from Exploratory Phase 2 Trial of FLX-787 in ALS
Nov 02, 2017: Concentric Analgesics Launches CA-008 Clinical Development Program in Post-Surgical Pain
Oct 30, 2017: Centrexion Therapeutics Announces Multiple Data Presentations on CNTX-4975 at the American College of Rheumatology Annual Meeting 2017
Oct 30, 2017: NEO6860 Phase II Data to be Presented at the American College of Rheumatology’s Annual Meeting
Oct 19, 2017: The World Health Organization Selects Tivanisiran as the International Nonproprietary Name for SYL1001
Oct 16, 2017: Flex Pharma Initiates CMT Phase 2 Trial with FLX-787 in US
Sep 27, 2017: Revive Therapeutics Applies to FDA for Orphan Drug Designation for Treatment of Autoimmune Hepatitis
Sep 26, 2017: Centrexion Therapeutics to Present Phase 2b data of Osteoarthritis Drug Candidate CNTX-4975 at the 11th Annual Pain and Migraine Therapeutics Summit
Aug 29, 2017: Centrexion Therapeutics to Present 6-Month Efficacy Data on CNTX-4975 for the Treatment of Chronic Pain Associated with Knee Osteoarthritis at PAINWeek 2017
Aug 01, 2017: Flex Pharma Initiates ALS Phase 2 Trial with FLX-787 in US
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products under Development by Indications, H1 2018 (Contd.1), H1 2018
Number of Products under Development by Indications, H1 2018 (Contd.2), H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Companies, H1 2018 (Contd.1)
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd.1), H1 2018
Products under Development by Companies, H1 2018 (Contd.2), H1 2018
Products under Development by Companies, H1 2018 (Contd.3), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Amgen Inc, H1 2018
Pipeline by Amorepacific Corp, H1 2018
Pipeline by BCN Peptides SA, H1 2018
Pipeline by Centrexion Therapeutics Corp, H1 2018
Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2018
Pipeline by DoNatur GmbH, H1 2018
Pipeline by Flex Pharma Inc, H1 2018
Pipeline by Grunenthal GmbH, H1 2018
Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2018
Pipeline by Medifron DBT Co Ltd, H1 2018
Pipeline by Neurim Pharmaceuticals Ltd, H1 2018
Pipeline by Pila Pharma AB, H1 2018
Pipeline by Sylentis SAU, H1 2018
Pipeline by Toray Industries Inc, H1 2018
Pipeline by Vitality Biopharma Inc, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd.1), H1 2018
Dormant Products, H1 2018 (Contd.2), H1 2018
Dormant Products, H1 2018 (Contd.3), H1 2018
Dormant Products, H1 2018 (Contd.4), H1 2018
Discontinued Products, H1 2018
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products under Development by Indications, H1 2018 (Contd.1), H1 2018
Number of Products under Development by Indications, H1 2018 (Contd.2), H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Companies, H1 2018 (Contd.1)
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd.1), H1 2018
Products under Development by Companies, H1 2018 (Contd.2), H1 2018
Products under Development by Companies, H1 2018 (Contd.3), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Amgen Inc, H1 2018
Pipeline by Amorepacific Corp, H1 2018
Pipeline by BCN Peptides SA, H1 2018
Pipeline by Centrexion Therapeutics Corp, H1 2018
Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2018
Pipeline by DoNatur GmbH, H1 2018
Pipeline by Flex Pharma Inc, H1 2018
Pipeline by Grunenthal GmbH, H1 2018
Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2018
Pipeline by Medifron DBT Co Ltd, H1 2018
Pipeline by Neurim Pharmaceuticals Ltd, H1 2018
Pipeline by Pila Pharma AB, H1 2018
Pipeline by Sylentis SAU, H1 2018
Pipeline by Toray Industries Inc, H1 2018
Pipeline by Vitality Biopharma Inc, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd.1), H1 2018
Dormant Products, H1 2018 (Contd.2), H1 2018
Dormant Products, H1 2018 (Contd.3), H1 2018
Dormant Products, H1 2018 (Contd.4), H1 2018
Discontinued Products, H1 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Top 10 Routes of Administration, H1 2018
Number of Products by Stage and Top 10 Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
COMPANIES MENTIONED
Amgen Inc
Amorepacific Corp
BCN Peptides SA
Centrexion Therapeutics Corp
Daewoong Pharmaceutical Co Ltd
DoNatur GmbH
Flex Pharma Inc
Grunenthal GmbH
Kyowa Hakko Kirin Co Ltd
Medifron DBT Co Ltd
Neurim Pharmaceuticals Ltd
Pila Pharma AB
Sylentis SAU
Toray Industries Inc
Vitality Biopharma Inc
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Top 10 Routes of Administration, H1 2018
Number of Products by Stage and Top 10 Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
COMPANIES MENTIONED
Amgen Inc
Amorepacific Corp
BCN Peptides SA
Centrexion Therapeutics Corp
Daewoong Pharmaceutical Co Ltd
DoNatur GmbH
Flex Pharma Inc
Grunenthal GmbH
Kyowa Hakko Kirin Co Ltd
Medifron DBT Co Ltd
Neurim Pharmaceuticals Ltd
Pila Pharma AB
Sylentis SAU
Toray Industries Inc
Vitality Biopharma Inc
